ArticleImmunoHorizons2026
Neurogranin negatively regulates gene expression and proinflammatory mediator release in allergen-activated mast cells.
Article in ImmunoHorizons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Mast cells are critical players in the maladaptive immune responses underlying biphasic reactions in allergic inflammation. Neurogranin (Ng) is an IQ domain-containing protein that sequesters Calmodulin under low [Ca2+] and negatively regulates calmodulin-mediated signaling such as calcineurin activation, in addition to downstream inflammatory responses. Previously described as brain specific, Ng has recently been identified in the spleen, bone marrow, and B lymphocytes, highlighting the need to investigate its negative regulatory role in other proinflammatory contexts. Here, we sought to determine the role of Ng in allergen-activated mast cells, to better understand the negative regulatory mechanisms that can potentially be exploited to help alleviate the severity of allergic inflammation. Using bone marrow-derived mast cells from wild-type (Nrgn+/+) and heterozygous (Nrgn+/-) mice, we identified that Ng is present in mast cells. It was determined that although Ng did not influence the development of mature mast cells or the extent of early-phase inflammation, a reduction in Ng significantly increased gene expression of IL6 and IL13, which was coupled with an increase in release of IL-6, IL-13, TNF, CCL1, CCL2, and CCL3. Together, this is the first study to identify Ng in mast cells, in addition to positioning its role as a negative regulator of mast cell responses following allergen activation. These data highlight the need for future research to further elucidate the role of Ng in IgE-mediated mast cell activation to better understand the regulatory mechanisms of these inflammatory cells in mast cell-driven normal and pathological contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.